Eric Osterag, MD, PhD, chief executive officer of Poseida Therapeutics Inc, discusses the company’s latest chimeric antigen receptor (CAR) T-cell product, P-BCMA-101 for patients with relapsed/refractory multiple myeloma. He highlights major benefits to this product and its potential for treatment of this patient population.
P-BCMA-101 is faster to make and cheaper by design because it only needs guanosine monophosphate (GMP) DNA and GMP-RNA. However, Osterag says the most significant thing about this product is that it ends up being 70-80% stem cell memory, unlike many other CAR T-cells.
CAR T-cells are incredible because a single cell can kill many cancer cells, including specific cancer cells. After administering these into a subject, the cells usually stop working from anywhere between a few weeks and few months, according to Osterag. The P-BCMA-101 product, however, can last potentially a lifetime.
For more information regarding anticancer targeted therapies and the latest advancements in multiple myeloma: [ Ссылка ]
